Medical Device | April 28, 2026
Concept Medical unveils promising 3-year data for sirolimus balloon therapy
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
Subscribe To Our Newsletter & Stay Updated
